2018
DOI: 10.14309/00000434-201810001-00701
|View full text |Cite
|
Sign up to set email alerts
|

Venous Thromboembolism (VTE) Prophylaxis in Inflammatory Bowel Disease (IBD) Flare-Ups

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

0
11
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(11 citation statements)
references
References 0 publications
0
11
0
Order By: Relevance
“…The need for multiple transfusions also did not differ in the study, where 5.4% of patients with hematochezia required ≥3 packed red blood cells transfusion compared to 6.6% without hematochezia in this cohort ( p = .63) 3 . Since hematochezia is secondary to a disease flare in 95% of patients with IBD, studies have also proven the safety of VTE prophylaxis in the presence of an IBD flare 3,5,6 . Ra et al demonstrated that among a cohort of 974 patients admitted for IBD flare, VTE prophylaxis did not significantly affect major and minor bleeding rates for patients who received pharmacologic prophylaxis as compared to those who did not (0.26 vs. 0 per 1000 person‐days, p = .7 for major bleeding; 4.18 vs. 2.53 per 1000 person‐days, p = .4 for minor bleeding).…”
Section: Why Withholding Pharmacologic Vte Prophylaxis In Ibd Patient...mentioning
confidence: 71%
See 3 more Smart Citations
“…The need for multiple transfusions also did not differ in the study, where 5.4% of patients with hematochezia required ≥3 packed red blood cells transfusion compared to 6.6% without hematochezia in this cohort ( p = .63) 3 . Since hematochezia is secondary to a disease flare in 95% of patients with IBD, studies have also proven the safety of VTE prophylaxis in the presence of an IBD flare 3,5,6 . Ra et al demonstrated that among a cohort of 974 patients admitted for IBD flare, VTE prophylaxis did not significantly affect major and minor bleeding rates for patients who received pharmacologic prophylaxis as compared to those who did not (0.26 vs. 0 per 1000 person‐days, p = .7 for major bleeding; 4.18 vs. 2.53 per 1000 person‐days, p = .4 for minor bleeding).…”
Section: Why Withholding Pharmacologic Vte Prophylaxis In Ibd Patient...mentioning
confidence: 71%
“…Despite the increased risk of VTE among IBD patients, thromboembolism prophylaxis rates remain low. Previous studies have demonstrated that fewer than 50% of hospitalized IBD patients routinely receive pharmacologic VTE prophylaxis 5–7 . Even in the absence of traditional VTE risk factors such as active malignancy, previous VTE, or known clotting disorder, IBD independently increases the overall risk of VTE threefold in all IBD patients as compared to the general population 8 .…”
Section: Why Withholding Pharmacologic Vte Prophylaxis In Ibd Patient...mentioning
confidence: 99%
See 2 more Smart Citations
“…24 Much of the previous VTE data come from either relatively small single-center series, large population data sets, or large claim databases that lack granular data. 25,26 We therefore aimed to add incrementally to the available literature using an enterprise-wide electronic medical record system to determine the 90-day rate of deep venous thromboembolism (DVT) and PE among all patients admitted for IBD, timing of DVT and PE events, and risk factors for DVT and PE with a focus on in-hospital and postdischarge chemoprophylaxis.…”
mentioning
confidence: 99%